Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 21, 2026
Key Takeaways on GLP-3R and Insulin Resistance
- Retatrutide (GLP-3R) is a triple agonist that activates GLP-1, GIP, and glucagon receptors at the same time, creating broader metabolic effects for insulin resistance than single or dual agonists.
- Phase 2 metabolomics analyses show retatrutide produces sustained improvements in biomarkers tied to insulin resistance, including branched-chain amino acids and fatty acid oxidation markers, maintained through 36–48 weeks.1
- Clinical data indicate retatrutide can reduce hepatic fat content by more than 80% in MASLD populations and improve HbA1c and fasting glucose in both diabetic and non-diabetic patients.1
- Compared with GLP-1 agonists like semaglutide, retatrutide’s added glucagon receptor activation increases energy expenditure and hepatic fat oxidation, creating a distinct pathway for improving insulin resistance.1
- At Mirror Plastic Surgery, board-certified FNP Ellie Pranckevicius delivers a concierge GLP-3R program with lab-guided dosing, batch-tested sourcing, and 24/7 support so you can explore whether triple-agonist therapy fits your metabolic profile.
How GLP-3R’s Triple-Agonist Mechanism Targets Metabolism
Retatrutide (LY3437943) is a triple receptor agonist that activates GLP-1, GIP, and glucagon receptors at once, creating metabolic effects that exceed those of dual or single agonists. Each receptor axis contributes a specific role.
- GLP-1 receptor activation drives glucose-dependent insulin secretion from pancreatic beta cells, reduces inappropriate glucagon release from alpha cells, slows gastric emptying, and suppresses appetite signals in the brain.
- GIP receptor activation amplifies insulin secretion in a glucose-dependent way, so it boosts insulin only when blood glucose is elevated, and it enhances adipose-tissue lipid signaling alongside GLP-1 pathways.
- Glucagon receptor activation increases energy expenditure through thermogenesis and promotes hepatic fat oxidation and adipose tissue breakdown beyond what GLP-1 or GIP activation alone can provide. Researchers hypothesize that concurrent GLP-1 and GIP driven insulin secretion counterbalances these effects to avoid net hyperglycemia.
Tirzepatide activates only GLP-1 and GIP receptors. Retatrutide’s added glucagon receptor agonism directly increases hepatic fat oxidation and energy expenditure in ways dual-agonist therapy does not match.
Evidence That GLP-3R Improves Insulin Resistance
Clinical metabolomics data show that retatrutide changes the biomarkers that define insulin resistance. A 2026 post-hoc metabolomics and lipidomics analysis of two randomized, placebo-controlled Phase 2 retatrutide trials (obesity trial: n=282; T2D trial: n=213) found that retatrutide treatment was associated with changes in metabolites linked to insulin resistance, including branched-chain amino acids and their catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains, in both participants with and without type 2 diabetes, sustained through 36–48 weeks.
Higher doses of retatrutide also altered a cluster of metabolites related to fatty acid oxidation, including 3-hydroxybutyrate, acetylcarnitine, free carnitine, and long-chain acylcarnitines. Mediation analyses indicate that these shifts contribute to weight reduction in participants with and without T2D.
Retatrutide’s triple agonism improves beta-cell function and glucose-dependent insulin release more than selective GLP-1 agonists. It also reduces inappropriate glucagon secretion that drives hepatic glucose production. The glucagon component works upstream on hepatic fat metabolism in ways pure GLP-1 agents do not, which supports improvements in insulin resistance and liver parameters.
Timeline for GLP-3R Improvements in Insulin Resistance
Phase 2 and Phase 3 trials outline how quickly metabolic markers respond to retatrutide. Key findings across the evidence base include the following.
- Trials show reductions in HbA1c, fasting plasma glucose, and waist circumference with retatrutide.1
- In patients with type 2 diabetes, retatrutide produced substantial weight loss and HbA1c reduction at 36 weeks, and many participants reached improved glycemic targets.1
- A 2026 network meta-analysis of randomized controlled trials found that retatrutide produced notable HbA1c reduction versus placebo among glucagon receptor agonists evaluated.1
- The metabolomics changes described earlier persisted through 36–48 weeks of treatment in both diabetic and non-diabetic participants, suggesting durable metabolic effects.
The metabolomics data suggest that fatty acid oxidation pathways begin to shift within the first weeks of treatment. The full magnitude of HOMA-IR relevant changes builds over the 36–48 week window observed in Phase 2 trials.
Clinical Signs of Insulin Resistance Reversal with GLP-3R
Evidence in non-diabetic and metabolic-syndrome populations is growing, with the strongest data in MASLD (metabolic dysfunction-associated steatotic liver disease). This group has high rates of insulin resistance even without overt diabetes. In a 2024 Phase 2a randomized placebo-controlled trial published in Nature Medicine (n=98, 24 weeks), retatrutide at 8 mg and 12 mg produced relative reductions in hepatic lipid content of 81.4% and 82.4% respectively versus 0.3% for placebo.1 Hepatic fat accumulation drives hepatic insulin resistance, so these reductions carry clinical significance beyond weight loss alone.
For prediabetes, tirzepatide offers a useful comparison. In a 176-week extension of SURMOUNT-1 (1,032 participants with obesity and prediabetes), tirzepatide reduced progression to type 2 diabetes to 1.3% versus 13.3% with placebo (HR 0.07).1 Retatrutide’s greater weight-loss magnitude and additional glucagon-mediated hepatic effects suggest at least comparable benefit in this group, although dedicated prediabetes trials have not yet reported primary endpoints.1
No clinical trials of retatrutide specifically in women with PCOS have been published, so direct human trial evidence for that subgroup is not yet available.
GLP-3R vs GLP-1R and Tirzepatide for Insulin Resistance
The following comparison highlights how retatrutide’s triple-agonist design differs from GLP-1 and dual-agonist therapies in mechanisms, metabolic impact, and tolerability.
Concierge GLP-3R Care at Mirror Plastic Surgery
Mirror Plastic Surgery’s GLP-3R program starts with a comprehensive 30–60 minute consultation that reviews full medical history alongside thyroid, liver, kidney, diabetes marker, and hormone panels. If current lab results are not available, Ellie orders them before starting any protocol. Custom dosing for non-diabetic patients with insulin resistance is tailored to individual lab findings rather than a generic weight-loss template.
Peptides come only from providers with rigorous batch testing, which protects product quality, purity, and dose accuracy. This safeguard matters because these compounds are not FDA-regulated. Patients receive clear reconstitution and self-administration instructions, often with video demonstrations, and have direct 24/7 text access to Ellie for questions, side-effect support, and refill coordination. The program is available in person at the St. Petersburg clinic or remotely across the United States.
Current expert guidance supports individualized prescribing based on patient risk profile, gradual dose escalation, proactive counseling, and regular assessment for adverse events, with targeted monitoring for renal dysfunction, pancreatitis, gallbladder disease, and musculoskeletal health when clinically indicated. Mirror Plastic Surgery’s protocol follows these principles, with dose escalation reviewed at each visit and slowed or reduced when tolerability requires adjustment.
Start your lab review and protocol design with Ellie.
Meet Your GLP-3R Practitioner: Ellie Pranckevicius, FNP-BC
Ellie Pranckevicius is a board-certified Family Nurse Practitioner and the lead practitioner for peptide therapies at Mirror Plastic Surgery. She earned her Bachelor’s in Health Science from Boston University on the premedical track, completed an aesthetics licensure program, and obtained both her Bachelor’s and Master’s in Nursing from the University of South Florida. Before becoming a nurse practitioner, Ellie worked at a high-end medical spa in Boston, where she developed a strong foundation in skin physiology, client care, and aesthetic assessment.
Her clinical background includes four years in the Neuroscience ICU at Tampa General Hospital, where she managed complex patients and gained a deep understanding of physiology, metabolic health, and recovery. This critical-care experience shapes her approach to GLP-3R dosing and monitoring in ways generalist telemedicine platforms do not match. Ellie’s practice philosophy mirrors dentistry: professional treatments create results, but lasting outcomes depend on patient understanding and consistent maintenance. She explains the physiology behind each recommendation in plain language and regularly tells patients when a service is not yet necessary, prioritizing long-term outcomes over short-term revenue.
Clarifying Common GLP-3R Misconceptions
FDA approval status. Retatrutide is currently in Phase 3 clinical trials and has not received FDA approval. Medically supervised compounding programs can still provide access, but unsupervised online purchase carries significant risk from unverified sourcing, inaccurate dosing, and lack of screening for contraindications.
Weight-loss-only perception. Metabolomics evidence shows that retatrutide’s effects on branched-chain amino acid catabolism, fatty acid oxidation, and hepatic lipid content differ from simple caloric restriction. These changes occurred in participants with and without type 2 diabetes and persisted through 36–48 weeks, which supports use for insulin resistance as a primary metabolic target, not just weight loss.
Stopping therapy. Discontinuing retatrutide will likely lead to gradual return of insulin resistance and weight regain, similar to the pattern seen with GLP-1 receptor agonists. Weight regain after retatrutide discontinuation has not been fully characterized in Phase 2 trials and is under evaluation in Phase 3 extension studies. Mirror Plastic Surgery discusses maintenance protocols with every patient from the start.
Muscle loss concerns. Current Phase 2 data do not show that retatrutide’s glucagon receptor agonism clearly improves lean-mass preservation compared with tirzepatide. Controlled head-to-head trials with matched weight loss are needed to test this idea. Even so, lean mass reduction occurs alongside much larger fat-mass loss, which improves the lean-to-fat tissue ratio overall.
Frequently Asked Questions About GLP-3R at Mirror Plastic Surgery
Is GLP-3R safe for people who do not have type 2 diabetes?
Retatrutide has been studied in adults with obesity or overweight without type 2 diabetes in Phase 2 trials, and metabolomics data confirm insulin-resistance-related changes in non-diabetic participants. At Mirror Plastic Surgery, non-diabetic patients complete a full lab panel, including fasting insulin, glucose, thyroid, liver, and kidney markers, before starting any protocol. Dosing is matched to individual physiology, and escalation is gradual to reduce gastrointestinal side effects. Patients with a personal or family history of medullary thyroid carcinoma, pancreatitis, or gallbladder disease receive additional evaluation before treatment.
How is Mirror Plastic Surgery’s GLP-3R program different from ordering retatrutide online?
Unregulated online sources for retatrutide create several risks, including lack of third-party batch testing, no confirmation of active ingredient concentration, no screening for contraindications, and no medical support if side effects occur. Mirror Plastic Surgery uses peptides only from providers with documented batch testing, performs a comprehensive medical history review and lab analysis before prescribing, and offers 24/7 direct access to Ellie throughout the program. This level of oversight is not available with unsupervised online purchase.
What lab markers does Mirror Plastic Surgery monitor during GLP-3R therapy?
The initial evaluation includes thyroid, liver, kidney, diabetes markers such as fasting glucose, fasting insulin, and HbA1c, along with hormone panels. These baselines allow Ellie to calculate HOMA-IR, identify contraindications, and set individualized targets. Follow-up labs are ordered at clinically appropriate intervals to track fasting insulin, HbA1c, lipid panels, and liver enzymes, and to monitor for any signs of renal stress or gallbladder involvement, consistent with current expert guidance for this drug class.
What should I expect in terms of side effects?
The most common side effects across retatrutide trials are gastrointestinal, including nausea, diarrhea, constipation, and vomiting. These effects are dose-dependent and usually mild to moderate. Mirror Plastic Surgery’s protocol uses gradual dose escalation, starting at a lower dose and titrating based on individual tolerability, which is the main strategy for reducing GI burden. Trials have also observed a modest, dose-dependent increase in heart rate of about 5–10 beats per minute, which is monitored. Patients with pre-existing cardiovascular conditions receive individualized evaluation before starting therapy.
Will I need to stay on GLP-3R indefinitely to maintain improvements in insulin resistance?
Insulin resistance is a chronic metabolic condition, and evidence from GLP-1 agents shows that benefits fade after discontinuation. Retatrutide will likely follow a similar pattern. Mirror Plastic Surgery discusses maintenance strategies with every patient from the first consultation, including the roles of nutrition, resistance training, and sleep in sustaining metabolic gains. The goal is to use the treatment window to build durable habits that reduce reliance on ongoing medication over time.
Conclusion: Is GLP-3R a Fit for Your Metabolic Health?
Retatrutide’s triple-agonist mechanism addresses insulin resistance through overlapping and complementary pathways. These include glucose-dependent insulin secretion, suppression of inappropriate glucagon release, hepatic fat oxidation, and sustained changes in branched-chain amino acid and fatty acid metabolite profiles that define insulin resistance at the cellular level. Evidence from Phase 2 and Phase 3 trials, metabolomics analyses, and network meta-analyses positions retatrutide as a highly potent agent for weight reduction and metabolic improvement, with a side-effect profile that calls for careful, individualized management.
Mirror Plastic Surgery’s concierge GLP-3R program, led by Ellie Pranckevicius, FNP-BC, delivers this therapy with lab-guided dosing, batch-tested sourcing, and one-on-one oversight that matches the complexity of triple-agonist treatment. Patients in St. Petersburg, Tampa, and across the United States can access the program in person or through telemedicine.
Schedule your metabolic evaluation and dosing consultation.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
